Engasertib

Engasertib
Identifiers
	IUPAC name 6-[4-(1-amino-3-hydroxycyclobutyl)phenyl]-1-ethyl-7-phenylpyrido[2,3-b][1,4]oxazin-2-one;
CAS Number	1313439-71-2;
PubChem CID	68299673;
IUPHAR/BPS	13743;
DrugBank	DB17697;
ChemSpider	115277122;
UNII	K2US8HW4TQ;
ChEMBL	ChEMBL5314970;
Chemical and physical data
Formula	C25H25N3O3
Molar mass	415.493 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCN1C(=O)COC2=C1C=C(C(=N2)C3=CC=C(C=C3)C4(CC(C4)O)N)C5=CC=CC=C5;
	InChI InChI=InChI=1S/C25H25N3O3/c1-2-28-21-12-20(16-6-4-3-5-7-16)23(27-24(21)31-15-22(28)30)17-8-10-18(11-9-17)25(26)13-19(29)14-25/h3-12,19,29H,2,13-15,26H2,1H3; Key:BPHCAPAOSHZYJY-UHFFFAOYSA-N;

Engasertib is an investigational new drug that is being evaluated by Vaderis Therapeutics for the treatment of hereditary haemorrhagic telangiectasia. It acts as a c-akt protein inhibitor.^[1]^[2]^[3]^[4]

References

↑ "Engasertib - Vaderis Therapeutics". AdisInsight. Springer Nature Switzerland AG.
↑ Al-Samkari H, Hessels J, Riera-Mestre A, Dupuis-Girod S, Van Zele T, Gómez Del Olmo V, et al. (November 2025). "Engasertib versus Placebo for Bleeding in Hereditary Hemorrhagic Telangiectasia". The New England Journal of Medicine. 393 (21): 2131–2141. doi:10.1056/NEJMoa2504411. PMID 41297007.
↑ Al-Samkari H, Picard D, Mager HJ (February 2026). "Engasertib in Hereditary Hemorrhagic Telangiectasia. Reply". The New England Journal of Medicine. 394 (8): 825–826. doi:10.1056/NEJMc2518633. PMID 41707157.
↑ Liang D, Lin Y, He L (February 2026). "Engasertib in Hereditary Hemorrhagic Telangiectasia". The New England Journal of Medicine. 394 (8): 825. doi:10.1056/NEJMc2518633. PMID 41707156.

This pharmacology-related article is a stub. You can help Wikipedia by adding missing information.